NBIX
Income statement / Annual
Last year (2024), Neurocrine Biosciences, Inc.'s total revenue was $2.36 B,
an increase of 24.81% from the previous year.
In 2024, Neurocrine Biosciences, Inc.'s net income was $341.30 M.
See Neurocrine Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$2.36 B |
$1.89 B |
$1.49 B |
$1.13 B |
$1.05 B |
$788.10 M |
$451.24 M |
$161.63 M |
$15.00 M |
$19.77 M |
| Cost of Revenue |
$34.00 M
|
$39.70 M
|
$23.20 M
|
$14.30 M
|
$10.10 M
|
$7.40 M
|
$4.89 M
|
$1.25 M
|
$35.90 M
|
$33.80 M
|
| Gross Profit |
$2.32 B
|
$1.85 B
|
$1.47 B
|
$1.12 B
|
$1.04 B
|
$780.70 M
|
$446.35 M
|
$160.37 M
|
-$20.90 M
|
-$14.03 M
|
| Gross Profit Ratio |
0.99
|
0.98
|
0.98
|
0.99
|
0.99
|
0.99
|
0.99
|
0.99
|
-1.39
|
-0.71
|
| Research and Development Expenses |
$731.10 M
|
$565.00 M
|
$463.80 M
|
$328.10 M
|
$275.00 M
|
$200.00 M
|
$160.52 M
|
$121.83 M
|
$94.29 M
|
$81.49 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$248.93 M
|
$169.91 M
|
$68.08 M
|
$32.48 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.01 B
|
$887.60 M
|
$752.70 M
|
$583.30 M
|
$433.30 M
|
$354.10 M
|
$248.93 M
|
$169.91 M
|
$68.08 M
|
$32.48 M
|
| Other Expenses |
$12.50 M
|
$143.90 M
|
$0.00
|
$105.30 M
|
$164.50 M
|
$154.27 M
|
$0.00
|
-$20,000.00
|
$13,000.00
|
$11,000.00
|
| Operating Expenses |
$1.75 B
|
$1.60 B
|
$1.22 B
|
$911.40 M
|
$708.30 M
|
$554.10 M
|
$409.46 M
|
$291.73 M
|
$162.37 M
|
$113.97 M
|
| Cost And Expenses |
$1.78 B
|
$1.64 B
|
$1.24 B
|
$925.70 M
|
$718.40 M
|
$561.50 M
|
$414.35 M
|
$292.99 M
|
$162.37 M
|
$113.97 M
|
| Interest Income |
$91.00 M
|
$0.00
|
$11.20 M
|
$3.80 M
|
$12.60 M
|
$19.21 M
|
$0.00
|
$0.00
|
$2.84 M
|
$1.93 M
|
| Interest Expense |
$0.00
|
$4.60 M
|
$7.10 M
|
$25.80 M
|
$32.80 M
|
$32.00 M
|
$30.53 M
|
$19.52 M
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$27.10 M
|
$21.30 M
|
$15.60 M
|
$10.90 M
|
$8.60 M
|
$7.45 M
|
$4.02 M
|
$2.40 M
|
$1.50 M
|
$1.01 M
|
| EBITDA |
$610.10 M |
$358.00 M |
$264.60 M |
$218.70 M |
$336.10 M |
$226.60 M |
$56.40 M |
-$120.62 M |
-$139.59 M |
-$87.92 M |
| EBITDA Ratio |
0.26
|
0.19
|
0.17
|
0.18
|
0.31
|
0.29
|
0.08
|
-0.81
|
-10.24
|
-5.03
|
| Operating Income Ratio |
0.24
|
0.13
|
0.17
|
0.17
|
0.3
|
0.28
|
0.08
|
-0.81
|
-9.82
|
-4.77
|
| Total Other Income/Expenses Net |
-$84.50 M
|
$81.20 M
|
-$35.10 M
|
-$1.10 M
|
-$56.30 M
|
-$25.80 M
|
-$15.05 M
|
-$11.18 M
|
$6.28 M
|
$5.27 M
|
| Income Before Tax |
$486.00 M
|
$332.10 M
|
$213.90 M
|
$101.40 M
|
$106.70 M
|
$46.50 M
|
$21.84 M
|
-$142.54 M
|
-$141.09 M
|
-$88.93 M
|
| Income Before Tax Ratio |
0.21
|
0.18
|
0.14
|
0.09
|
0.1
|
0.06
|
0.05
|
-0.88
|
-9.41
|
-4.5
|
| Income Tax Expense |
$144.70 M
|
$82.40 M
|
$59.40 M
|
$11.80 M
|
-$300.60 M
|
$9.50 M
|
$730,000.00
|
$17.10 M
|
-$7.72 M
|
-$6.27 M
|
| Net Income |
$341.30 M
|
$249.70 M
|
$154.50 M
|
$89.60 M
|
$407.30 M
|
$37.00 M
|
$21.11 M
|
-$142.54 M
|
-$141.09 M
|
-$88.93 M
|
| Net Income Ratio |
0.14
|
0.13
|
0.1
|
0.08
|
0.39
|
0.05
|
0.05
|
-0.88
|
-9.41
|
-4.5
|
| EPS |
3.4 |
2.56 |
1.61 |
0.95 |
4.37 |
0.4 |
0.22 |
-1.62 |
-1.63 |
-1.05 |
| EPS Diluted |
3.29 |
2.47 |
1.56 |
0.92 |
4.16 |
0.39 |
0.22 |
-1.62 |
-1.63 |
-1.05 |
| Weighted Average Shares Out |
$100.40 M
|
$97.70 M
|
$95.80 M
|
$94.60 M
|
$93.10 M
|
$91.63 M
|
$95.40 M
|
$87.99 M
|
$86.56 M
|
$84.50 M
|
| Weighted Average Shares Out Diluted |
$103.70 M
|
$101.00 M
|
$98.90 M
|
$97.90 M
|
$97.80 M
|
$95.73 M
|
$95.40 M
|
$88.09 M
|
$86.71 M
|
$84.50 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
